IN8bio, Inc.(NASDAQ:INAB) 
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I cli...
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 4.80
H 4.80
L 4.20
C 4.50
V 1,411,333
10EMA 4.50
20EMA 4.50
60EMA 4.50
120EMA 4.50
250EMA 4.50